Physician profile
Benjamin Ferry
NPI 1174057285
$588.67
in general payments reported to CMS, 2019-2025
18 companies · $151 in 2025
The $151 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.12 · 2022: $80.68 · 2023: $64.88 · 2024: $275 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.10 | 2024-2025 | Caplyta |
| Bioventus LLC | $77.03 | 2022-2024 | Durolane, Durolane |
| Abbvie INC. | $47.01 | 2024 | |
| Dexcom, INC. | $42.77 | 2023-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $42.17 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $40.01 | 2022-2024 | Rexulti |
| Ascendis Pharma Endocrinology INC | $39.88 | 2025 | Yorvipath |
| Depuy Synthes Sales INC. | $30.12 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $28.03 | 2024 | Qelbree |
| Xeris Pharmaceuticals, INC. | $22.18 | 2024 | Gvoke Hypopen |
| Lilly USA, LLC | $21.56 | 2025 | Mounjaro, Zepbound |
| Beta Bionics, INC. | $18.36 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Takeda Pharmaceuticals U.S.A., INC. | $17.99 | 2023 | Trintellix |
| Insulet Corporation | $17.09 | 2024 | Omnipod |
| Amgen INC. | $16.06 | 2024 | Prolia, Evenity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $14.90 | 2025 | Lybalvi |
| Axsome Therapeutics, INC. | $14.41 | 2024 | Auvelity |
| Cequr Corporation | $14.00 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Ferry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.